CD163 and breast cancer: A meta-analysis of 16 studies assessing the relation of CD68 + , CD163 + and/or CD206 + TAMs with survival in primary, adjuvant- and neoadjuvant-treated patients with breast cancer, found that CD68 was a better outcome predictor than CD163 and CD206 [29].